CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
release announcing that an abstract exploring the application of
B-cell antigen, CD20, for targeted Chimeric Antigen Receptor T
cells (CAR-T) therapy has been accepted for publication in
conjunction with the 2017 American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago to be held from June 2 to June
6, 2017. A copy of the press release and the abstract is attached
hereto as Exhibit 99.1 and Exhibit 99.2, respectively.
|
(d)
|
Exhibits
|
|
|
99.1
|
Press Release, dated May 19, 2017
|
|
|
99.2
|
Abstract
|
About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Recent Trading Information
CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) closed its last trading session 00.00 at 6.30 with 42,576 shares trading hands.